Phreesia (NYSE:PHR) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Phreesia (NYSE:PHR) from a buy rating to a strong-buy rating in a research note published on Saturday morning.

Other analysts have also recently issued reports about the stock. Royal Bank Of Canada assumed coverage on shares of Phreesia in a research report on Friday, January 9th. They set a “moderate buy” rating and a $26.00 price target for the company. Zacks Research downgraded Phreesia from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, January 6th. Needham & Company LLC reiterated a “buy” rating and set a $35.00 target price on shares of Phreesia in a report on Monday, December 8th. Citigroup reduced their price target on Phreesia from $29.00 to $25.00 and set a “buy” rating on the stock in a research report on Friday, January 9th. Finally, JPMorgan Chase & Co. lowered their price objective on shares of Phreesia from $32.00 to $29.00 and set an “overweight” rating for the company in a research report on Tuesday, December 9th. Seventeen investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $29.76.

Phreesia Stock Down 1.7%

PHR opened at $13.21 on Friday. Phreesia has a 1 year low of $13.09 and a 1 year high of $32.76. The firm has a 50 day moving average price of $17.03 and a 200 day moving average price of $22.27. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.44 and a current ratio of 2.44. The company has a market cap of $796.13 million, a PE ratio of -132.04 and a beta of 0.65.

Phreesia (NYSE:PHR) last announced its quarterly earnings results on Monday, December 8th. The company reported $0.10 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.01) by $0.11. Phreesia had a negative net margin of 1.16% and a negative return on equity of 1.31%. The firm had revenue of $120.33 million for the quarter, compared to analysts’ expectations of $119.98 million. During the same period in the previous year, the company posted ($0.25) earnings per share. Phreesia’s revenue was up 12.7% compared to the same quarter last year. Sell-side analysts expect that Phreesia will post -1.1 earnings per share for the current year.

Insider Activity at Phreesia

In other Phreesia news, insider David Linetsky sold 6,106 shares of the stock in a transaction on Thursday, January 8th. The shares were sold at an average price of $17.01, for a total transaction of $103,863.06. Following the transaction, the insider directly owned 231,723 shares in the company, valued at $3,941,608.23. This represents a 2.57% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, SVP Amy Beth Vanduyn sold 2,602 shares of the firm’s stock in a transaction on Thursday, January 8th. The stock was sold at an average price of $17.01, for a total transaction of $44,260.02. Following the transaction, the senior vice president directly owned 160,238 shares of the company’s stock, valued at approximately $2,725,648.38. This represents a 1.60% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 60,766 shares of company stock worth $1,013,817. 5.50% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Phreesia

Several large investors have recently modified their holdings of the stock. Raymond James Financial Inc. increased its holdings in Phreesia by 2.7% in the second quarter. Raymond James Financial Inc. now owns 14,049 shares of the company’s stock valued at $400,000 after buying an additional 375 shares during the last quarter. PNC Financial Services Group Inc. grew its position in shares of Phreesia by 2.8% in the 2nd quarter. PNC Financial Services Group Inc. now owns 19,983 shares of the company’s stock worth $569,000 after acquiring an additional 540 shares in the last quarter. Diversified Trust Co grew its position in shares of Phreesia by 1.7% in the 3rd quarter. Diversified Trust Co now owns 45,822 shares of the company’s stock worth $1,078,000 after acquiring an additional 780 shares in the last quarter. Oppenheimer Asset Management Inc. increased its holdings in shares of Phreesia by 9.9% in the 2nd quarter. Oppenheimer Asset Management Inc. now owns 8,803 shares of the company’s stock valued at $251,000 after acquiring an additional 792 shares during the last quarter. Finally, Alliancebernstein L.P. raised its position in shares of Phreesia by 1.3% during the 3rd quarter. Alliancebernstein L.P. now owns 62,712 shares of the company’s stock valued at $1,475,000 after acquiring an additional 812 shares in the last quarter. Institutional investors own 92.10% of the company’s stock.

Phreesia Company Profile

Phreesia, Inc (NYSE: PHR) is a provider of patient intake management solutions designed to streamline front-office workflows for healthcare organizations. The company’s cloud-based platform digitizes patient registration, appointment scheduling, insurance verification, consent documentation and payment collection through touchscreen kiosks, tablets and mobile devices. By replacing paper forms and manual processes, Phreesia enhances data accuracy, reduces administrative burden and improves the patient experience.

Founded in 2000 by Chaim Indig and headquartered in Burlington, Massachusetts, Phreesia offers a modular software suite that integrates with electronic medical record (EMR) and practice management systems.